18.11.2020 • NewsElementis

Elementis Rejects Takeover Bid

Elementis has rejected a takeover bid from US specialty minerals firm Minerals Technologies Inc (MTI).

The New York City-based group revealed that it had made a bid on Nov. 5 to acquire the UK specialty chemicals firm, but the Elementis board rebuffed the all-cash offer, stating it significantly undervalued the firm and its future prospects.

The bid of $1.41 per share represented a 31% premium over Elementis’ share price on Nov. 4.

According to UK law, MTI now has until Dec. 10 to state whether or not it intends to make a formal and public offer for Elementis.

Both companies supply materials derived from mined minerals. Elementis also produces specialty chemicals for consumer and industrial applications and regards itself as the leading global producer of chromium chemicals. It reported sales of $874 million last year.

With annual sales of about $1.8 billion, MTI is a leading supplier of bentonite and bentonite-related products, as well as chromite and leonardite, to industrial and consumer markets globally. It also produces and sells synthetic mineral product precipitated calcium carbonate (PCC).

MTI said it is now considering its position, adding that there is no certainty that it will make any further proposal or firm offer, although any offer would likely be solely in cash.

Author: Elaine Burridge, Freelance Journalist

Elementis has rejected a takeover bid from US specialty minerals firm Minerals...
Elementis has rejected a takeover bid from US specialty minerals firm Minerals Technologies Inc (MTI). According to UK law, MTI now has until Dec. 10 to state whether or not it intends to make a formal and public offer for the UK specialty chemicals firm. (c) Khoa

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.